You are here: Industry Insights > BMS

News List

EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients pharmatimes
August 03, 2021
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...
BMS 2Q Revenues up 16% contractpharma
August 02, 2021
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer pharmatimes
July 01, 2021
The European Commission (EC) has approved Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy immunotherapy regimen for the treatment of certain metastatic colorectal patients (mCRC), the company announced 29th.
BMS’ CAR T therapy Abecma moves closer toward EU approval pharmatimes
June 29, 2021
Bristol Myers Squibb’s (BMS) CAR T cell therapy Abecma has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of relapsed and ...
BMS exercises option for US licence of Prothena’s Alzheimer’s antibody pharmaceutical-technology
June 28, 2021
Bristol Myers Squibb (BMS) has exercised an option under a neuroscience research and development partnership, to obtain an exclusive US licence to Prothena’s anti-tau antibody, PRX005.
Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
June 21, 2021
Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients pharmatimes
June 16, 2021
Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.
ProCell for Patient Project to Develop Automated Production Unit for CAR-T Cell Therapies contractpharma
June 11, 2021
Standardized and automated manufacturing aims to reduce the amount of work on producing CAR-T cells by 50 percent.
Opdivo combos show OS benefit in advanced oesophageal cancer pharmatimes
June 10, 2021
Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients.
Bristol Myers faces $6.4bn lawsuit over cancer drug delay pharmaceutical-technology
June 07, 2021
UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page